适用于:
WB, IPmore details 不适用于:
Flow Cyt (Intra),ICC/IF,IHC-Fr or IHC-P
种属反应性
与反应:
Mouse, Rat 不与反应:
Human
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
阳性对照
WB: RAW 264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 100ng/ml lipopolysaccharide (LPS) for 4h then add 1000ng/ml BFA for another 3h whole cell lysate, HUVEC treated with 0.5 µg/ml LPS, then with 0.3 µg/ml BFA, NR8383 treated with 0.1 µg/ml LPS, then with 1 µg/ml BFA
IP: RAW264.7 treated with 0.1 µg/ml LPS, then with 1ug/ml BFA, HUVEC treated with 0.5 ug/ml LPS, then with 0.3 µg/ml BFA, NR8383 cells treated with 0.1 µg/ml LPS, then with 1 ug/ml BFA.
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
形式
Liquid
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Is unsuitable for Flow Cyt (Intra),ICC/IF,IHC-Fr or IHC-P.
靶标
功能
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
疾病相关
Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Lane 1 : Rat cerebral cortex tissue lysate Lane 2 : Rat cerebellum tissue lysate Lane 3 : Rat hippocampus tissue lysate Lane 4 : Rat spinal cord tissue lysate Lane 5 : Rat small intestine tissue lysate Lane 6 : Rat kidney tissue lysate Lane 7 : Rat skin tissue lysate Lane 8 : RAW 264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate Lane 9 : RAW 264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 100ng/ml lipopolysaccharide (LPS) for 4h then add 1000ng/ml BFA for another 3h whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Normal tissues express undetectable level of TNF alpha, IL-1 beta and IL-6 proteins. IL-1 beta and TNF alpha could be good controls validating the increased IL-6 level after drug treatment.
IL-6 was immunoprecipitated from 0.35 mg RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 0.1 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug with ab259341 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259341 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug
Lane 2: ab259341 IP in RAW264.7 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate
Lane 3:Rabbit monoclonal IgG (ab172730) instead of ab259341 in RAW264.7 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes
Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
All lanes : Anti-IL-6 antibody [EPR23819-11] (ab259341) at 1/1000 dilution
Lane 1 : Untreated NR8383 (rat lung macrophage (alveolar)) whole cell lysate Lane 2 : NR8383 (rat lung macrophage (alveolar)) treated with 0.1 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 1 µg/ml Brefeldin A (BFA) added for 3 hours whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
IL-6 was immunoprecipitated from 0.35 mg NR8383 (rat lung macrophage (alveolar)) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug with ab259341 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259341 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: NR8383 (rat lung macrophage (alveolar)) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug
Lane 2: ab259341 IP in NR8383 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab259341 in NR8383 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Zhang L et al.Mechanism of arterial injury exacerbated by hyperhomocysteinemia in spontaneously hypertensive rats.Sci Rep 13:2482 (2023).
PubMed: 36774389
Wang T et al.LncTUG1 ameliorates renal tubular fibrosis in experimental diabetic nephropathy through the miR-145-5p/dual-specificity phosphatase 6 axis.Ren Fail 45:2173950 (2023).
PubMed: 36794657
Che Z et al.Melatonin alleviates alcoholic liver disease via EGFR-BRG1-TERT axis regulation.Acta Pharm Sin B 13:100-112 (2023).
PubMed: 36815038
Mao D et al.HDAC2 exacerbates rheumatoid arthritis progression via the IL-17-CCL7 signaling pathway.Environ Toxicol 38:1743-1755 (2023).
PubMed: 37021908
Liu S et al.MiR-30e-5p deficiency exerts an inhibitory effect on inflammation in rheumatoid arthritis via regulating Atl2 expression.Arch Rheumatol 38:119-128 (2023).
PubMed: 37235116